Optimizing Treatments for Heart Failure During Hospitalization

Decompensated Heart Failure Clinical Trial

— OPTICARD  

Official title:

Optimizing Treatments for Heart Failure During Hospitalization

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05910437
• Other study ID #: 2022PI115
• Status: Not yet recruiting
• Start date: September 2023
• Est. completion date: July 2024

Study information

• Verified date: August 2023
• Source: Central Hospital, Nancy, France
• Contact: Nicolas GIRERD, MD-PhD
• Phone: (0)3 83 15 73 22
• Email: cic[@]chru-nancy.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Heart failure reaches 1.5 million people in France and is responsible for 200,000 hospitalizations per year.

Over the past ten years, new therapies have emerged (treatment of martial deficiency, Entresto, iSGLT2).

Hospitalization in a context of acute heart failure is a moment of choice in the history of the disease to introduce recommended treatments under closer supervision (clinical, biological) than in ambulatory, and allows a decrease in hospitalizations, morbidity and mortality.

The purpose of this study is to describe the introduction of heart failure drugs (including iSGLT2) in real-life settings in patients hospitalized for decompensated heart failure.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 200
• Est. completion date: July 2024
• Est. primary completion date: July 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient = 18 years

• Hospitalized (=24h) for decompensated heart failure in cardiology.

Exclusion Criteria:

• Patient opposition participation in research and use of data.

Related Conditions & MeSH terms

• Decompensated Heart Failure
• Heart Failure

Intervention

Other:
• Hospitalized patient for decompensated heart failure
Describe the evolution of heart failure medications during hospitalization for decompensated heart failure.

Locations

Country	Name	City	State
France	Chr Metz Thionville	Ars-Laquenexy
France	CHRU de NANCY	Vandœuvre-lès-Nancy

Sponsors (1)

Lead Sponsor	Collaborator
Central Hospital, Nancy, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prescription score	Prescription score, ranging from 0 to 10, each type of heart failure treatment (IEC/ARA2, Sacubitril, betablockers, SGLT2i, MRA) being evaluated on a scale of 2.	During hospitalisation for decompensated heart failure (up to 10 days)
Secondary	serum concentration of creatinine	Creatinine measured at admission and discharge	During hospitalisation for decompensated heart failure (up to10 days)
Secondary	serum concentration of potassium	Potassium measured at admission and discharge	During hospitalisation for decompensated heart failure (up to 10 days)
Secondary	Concentration of hemoglobin	hemoglobin measured at admission and discharge	During hospitalisation for decompensated heart failure (up to 10 days)
Secondary	All cause Death		6 months
Secondary	Rate of hospitalization for heart failure		6 months